Siemens Healthcare, Molecular Imaging CEO Britta Fuenfstueck commented: "Siemens and Avid are organizations committed to changing the way chronic diseases are diagnosed and managed. Together, we share the view that new PET molecular imaging agents, such as Florbetapir, could have a major impact on health care for our aging population. We are pleased to be working with Avid on this exciting development and believe it fits well with our mission to deliver, expand, and advance the science of molecular imaging to the benefit of health care providers and their patients."

Avid's Florbetapir was the first -amyloid imaging compound to enter multi-center, IND clinical studies in the U.S., and has now been studied in more than a dozen trials in subjects ranging from cognitively normal individuals to those with Alzheimer's dementia. A pivotal Phase III registration study which was initiated early last year in the U.S. is nearing completion, and the compound is currently in additional clinical studies in the E.U., South America, Australia and Asia.

Source Avid Radiopharmaceuticals, Inc.